Announcement PDF Annual Report 2026 Transforming Clinical Evidence into Commercial Growth I 2026 Annual Report II Transforming Clinical Evidence into Commercial Growth Meeting one of oncology’s greatest unmet needs requires more than innovation—it demands clinical evidence, regulatory progress and commercial execution. Throughout FY26, OncoSil Medical Limited (“OncoSil Medical” or “the Company”) delivered meaningful milestones that strengthened its clinical foundation, expanded market access and positioned the Company for its next phase of growth. THE UNMET NEED Fighting One of the World’s Deadliest Cancers Pancreatic cancer remains one of the most challenging cancers to diagnose and treat. Often detected at an advanced stage, the disease is associated with poor survival outcomes and limited treatment options. Despite advances in systemic therapies over recent years, long-term outcomes for many patients remain largely unchanged. For patients diagnosed with unresectable locally advanced pancreatic cancer (LAPC), treatment is typically focused on controlling disease progression and extending survival. While chemotherapy regimens such as FOLFIRINOX and gemcitabine-based therapies have improved outcomes, many patients ultimately experience local tumour progression, significant symptoms, and limited opportunities for curative surgery. III IV • More than 80% of patients are not eligible for surgery at diagnosis. • Locally advanced disease frequently involves invasion of major blood vessels, adding significant risk thereby limiting opportunities for surgical resection. • Increasing resection rates remains one of the key objectives of modern pancreatic cancer management. • Many patients ultimately experience local disease progression despite systemic therapy. OncoSil™ addresses one of the most important objectives in pancreatic cancer treatment: increasing the number of patients who can progress to surgical resection. By delivering highly targeted intratumoural radiation in addition to standard chemotherapy, OncoSil™ enhances local tumour control at the site of disease. This approach supports tumour downstaging, expands opportunities for surgical intervention and addresses a critical unmet need in the management of unresectable LAPC. Growing clinical and real-world evidence continues to reinforce the value of OncoSil™ as a treatment designed not only to control disease, but to create a pathway to surgery for patients who would otherwise have limited options. The Challenge The Opportunity FY26 AT A GLANCE • Recruitment completed in PANCOSIL Trial • Recruitment completed in TRIPP-FFX Trial • Preliminary results of PANCOSIL Trial presented at CIRSE 2025 V July September • Dr Thomas Duthy appointed as Non- Executive Chairman • First commercial OncoSil™ treatments in Germany and Portugal October 2025 • First commercial OncoSil™ treatment in the United Kingdom • First successful hot (radio-activated) production test run at Sydney facility • TRIPP-FFX Trial completes Last Patient Last Visit • OSPREY Interim Results presented at ESGE Days 2026 • TGA Approval received VI December January May • TRIPP-FFX Trial meets co-primary endpoints • Final step reached for HDE with US FDA • TRIPP-FFX abstract accepted for oral presentation at ESMO GI 2026 June 2026 STRENGTHENING THE CLINICAL EVIDENCE OSPREY Registry What is OSPREY? OSPREY (OncoSil Pancreatic Cancer Post-Marketing Clinical Registry) is the largest prospective real-world registry evaluating the use of OncoSil™ device in patients with unresectable LAPC. Unlike controlled clinical trials, OSPREY reflects routine clinical practice across multiple countries and treatment centres, providing valuable insight into how patients perform outside of highly selected study populations. VII Key Findings VIII Why Real-World Data Matters Real-world evidence is increasingly recognised by clinicians, regulators and payers as a critical component of healthcare decision making. OSPREY helps answer important questions: • How does OncoSil™ perform in routine practice? • Can outcomes observed in clinical studies be replicated in broader patient populations? • What treatment patterns emerge as clinician experience grows? No Serious Adverse Device Effects (SADEs) or Grade ≥3 Adverse Device Effects (ADEs) reported Median Overall Survival from diagnosis of 20.6 and 22.0 months, respectively, in the ≤4 and 4–12 months 1st-line cohorts, and 10.5 months in patients implanted ≤4 months from starting 2nd-line chemo Surgical resection in 16.7% of patients implanted ≤4 months of 1st-line chemo, 15.8% of patients implanted at 4–12 months of 1st-line chemo and 10.0% of the 2nd-line cohort implanted at ≤4 months Enrolment in the registry is ongoing (≥80 patients enrolled to date) and follow-up continues 1 1 0(0) 0(0) 7/9(77.8) 1/10(10.0) 1/1(100) 0(0) 17.0(1 1.3-20.0) 10.5(8.4-12.9) 3 0 (0) 0 (0) nc - - - - - 1 0 (0) 0 (0) 1/1 (100) - - - - - 22 0(0) 0(0) 18/18(100) 3/19(15.8) 3/3(100) 0(0) 22.0(17.2-22.7) 20.0(16.0-22.2) 1 0 (0) 0 (0) 0/1 (0) - - - 21.7 3.0 3rd - Line ≤4 months 2nd - Line ≤4 months 25 0(0) 0(0) 14/17(82.4) 3/18(16.7) 1/3(33.3) 2/3(66.7) 20.6(16.9-20.1) 17.3(15.7-23.7) Number of patients Grade ≥3 ADES Grade ≥3, n(%) Serious ADES (SADES) Surgically Resected with Curative Intent n/n (%) Overall Survival, months; median (95% CI) R0 resection margin R1 resection margin From Diagnosis From Commencing Current Chemo Line LDCR12 weeks a , n/n (%) Any Grade, n(%) ≤4 months Implant Timing vs. Start of Chemo Line 4-12 months 1st - Line Concurrent Chemotherapy Line 4-12 months >12 months STRENGTHENING THE CLINICAL EVIDENCE TRIPP-FFX│Expanding the Clinical Potential of OncoSil™ TRIPP-FFX at a Glance • Randomised, non-comparative Phase II study • Evaluated OncoSil™ in addition to FOLFIRINOX chemotherapy vs. FOLFIRINOX alone • Experimental arm benchmarked against historical control data • Control arm included to validate historical outcomes • Not powered for formal statistical comparison between study arms • Designed to support EU-MDR (European Union Medical Device Regulation) clinical evidence requirements • Generates clinical evidence to support expansion of the OncoSil™ label to include use in addition to FOLFIRINOX IX Key Findings X TRIPP-FFX met both co-primary endpoints, supporting the use of OncoSil™ alongside standard-of-care FOLFIRINOX chemotherapy in patients with unresectable LAPC. Investigators concluded that toxicities associated with the addition of OncoSil™ to FOLFIRINOX chemotherapy were limited and manageable. Encouraging efficacy outcomes observed, including 82.2% (95% Confidence Interval (CI) 65-90%) Local Disease Control Rate (LDCR) at 16 weeks and 18.3 months of median overall survival in patients treated with OncoSil™ plus FOLFIRINOX chemotherapy. Historically, OncoSil™ has been used alongside gemcitabine-based chemotherapy. Positive TRIPP-FFX results demonstrate that the therapy can potentially be integrated with FOLFIRINOX treatment pathways, significantly expanding the addressable patient population. The Company expects to submit a Change Notification to the Company’s EU & UK Notified Body in late 1H FY27 to add FOLFIRINOX to the approved OncoSil™ product label. The TRIPP-FFX dataset supports regulatory submissions seeking approval to expand the approved indication for OncoSil™ to include use with FOLFIRINOX. A successful label expansion would: • Increase eligible patient populations • Support broader physician adoption • Strengthen reimbursement discussions • Accelerate commercial growth What These Results Mean Path to Label Expansion STRENGTHENING THE CLINICAL EVIDENCE TRIPP-FFX│Expanding the Clinical Potential of OncoSil™ Expert Perspectives The encouraging findings of the TRIPP-FFX study were further reinforced by the perspectives of the study’s Principal Investigators, who highlighted the clinical relevance of achieving both primary endpoints, the consistency of the data with previous evidence, and the study’s contribution to advancing multidisciplinary care for patients with unresectable LAPC. XI XII Michele Milella Professor of Medical Oncology, University of Verona, Italy & Principal Investigator of TRIPP-FFX Study: Giuseppe Malleo Associate Professor of Surgery at the University of Verona, Italy & Principal Investigator of TRIPP-FFX Study: “As TRIPP-FFX was designed as a randomized but non-comparative study, the significance of these findings lies in the successful achievement of the predefined clinical endpoints and the consistency of the overall data, with the control arm serving primarily as a benchmark against historical outcomes rather than for direct statistical comparison. In this context, the results are consistent with previously reported findings from historical datasets, including the PANCO trial and the OSPREY Registry and favourably compare with chemotherapy alone or the combination of chemotherapy and other forms of local treatment commonly used in this difficult-to-treat disease setting.” “The TRIPP-FFX study marks an important step forward in the treatment of unresectable locally advanced pancreatic cancer, particularly from a multidisciplinary care perspective. The achievement of both primary endpoints supports the continued clinical development of the OncoSil™ device and adds to the growing body of evidence generated through previous studies and real- world experience. From a surgical standpoint, the study confirms the possibility to downstage selected patients towards surgical resection. Further detailed analysis will help us better understand which patients may benefit the most, and I would like to acknowledge the strong commitment of everyone involved in the study, especially the patients and clinical teams whose contribution made these results possible.” EXPANDING THE CLINICAL POTENTIAL OF ONCOSIL XIII PANCOSIL (Investigator-Initiated Study) Opening the Door to a New Clinical Specialty Expanding Access Through Interventional Radiology PANCOSIL was designed to evaluate a novel CT (Computed Tomography)-guided percutaneous delivery approach for the OncoSil™ device, with the potential to expand the approved delivery method beyond endoscopic ultrasound (EUS)-guided implantation. Successful validation of this approach would support broader access to OncoSil™ by enabling treatment through a well- established, globally available minimally invasive procedure performed under CT guidance. │ XIV Why This Matters Interventional Radiologists are highly experienced in image-guided, minimally invasive procedures and routinely perform percutaneous tumour interventions across a wide range of cancers. This specialty is also familiar with handling radioactive materials and delivering image-guided therapies, making it well positioned to adopt OncoSil™ if the delivery approach is approved. The significance of PANCOSIL extends beyond clinical feasibility. A successful outcome could: • Significantly increase the number of physicians able to deliver OncoSil™ treatment • Reduce adoption barriers at treatment centres by leveraging existing CT-guided procedural capabilities • Provide greater procedural flexibility where EUS expertise or infrastructure is limited • Improve patient access by enabling treatment at a broader range of hospitals and cancer centres • Support international commercial expansion by broadening the addressable clinical user base • No procedure-related mortality • Two (10%) of the 20 patients experienced CTCAE (Common Terminology Criteria for Adverse Events) grade 3 serious adverse events within 90 days; no clinical sequalae; both patients recovered. • 90% technical success rate • 20.6 months median overall survival (OS) from diagnosis OncoSil Medical is targeting submission for a label extension in 1H FY27, seeking approval for CT-guided percutaneous implantation of the OncoSil™ device. Key Findings FROM EVIDENCE TO IMPACT EUROPEAN COMMERCIAL TRACTION│Expanding Adoption Across Europe Commercially Active Implanting Centres The number of commercially active implanting centres has continued to grow across Europe, reflecting increasing physician confidence, growing clinical experience and expanding utilisation of OncoSil™. With additional centres expected to become active throughout FY27, the Company remains well positioned to accelerate commercial adoption across existing and new markets. XV XVI Commercially Active Implanting Centres 60 50 40 30 20 10 0 FY24 FY25 FY26 1H FY27 Actual Forecast GERMANY│Unlocking Europe’s Largest Reimbursement Opportunity Why Germany Matters Germany represents Europe’s largest and most strategically important pancreatic cancer market. The country’s reimbursement framework creates a pathway for innovative technologies to gain access while generating real-world evidence and supporting long-term adoption. XVII FROM EVIDENCE TO IMPACT XVIII Understanding the G-BA Opportunity The Federal Joint Committee (G-BA) is Germany’s highest decision- making body for healthcare reimbursement within the country’s statutory health insurance system, which covers the vast majority of the population. The G-BA determines which medical treatments, procedures and technologies are eligible for reimbursement based on clinical evidence, patient benefit and health economic considerations. For innovative medical technologies, the G-BA may approve the conduct of a clinical reimbursement study to generate the evidence needed to support future funding decisions. As Germany represents the largest healthcare market in Europe, successful progression through the G-BA process is widely regarded as an important milestone for companies seeking long-term reimbursement, clinical adoption and broader market access across Europe. The top 40 German pancreatic cancer centres performed approximately 4,400 complex pancreatic surgeries in 20242 , accounting for ~40% of all such procedures nationwide. These high-volume centres represent our primary targets for commercial adoption, alongside their anticipated participation in the G-BA trial.3 References: 1. Globocan 2025 data 2. https://www.aok.de/pp/hintergrund/mindestmengen/mindestmengen-transparenzkarte-2026/ 3. The centres with appropriate nuclear medicine facilities capable of delivering OncoSilTM device Population ~84 million Pancreatic Cancer Incidence p.a.1 22,587 Pancreatic Cancer Incidence p.a.1 $264 million Locally Advanced Pancreatic Cancer 6,776 GERMANY Progress to Date • G-BA approval achieved, trial expected to commence in 1H FY27 • Growing physician engagement • First patient treated at Germany in October 2025 (outside of trial) • Increasing number of trained centres • Positive clinical experience across hospitals XIX FROM EVIDENCE TO IMPACT XX Germany Reimbursement Opportunity The proposed German reimbursement study represents a significant strategic opportunity that extends beyond direct revenue generation. Key benefits include: • Generation of Level 1 clinical evidence, the highest standard of evidence for clinicians, regulators and reimbursement bodies • Potential pathway to national reimbursement in Germany following positive study outcomes • Opportunity for inclusion in German consensus treatment guidelines • Potential incorporation into broader European treatment guidelines • Valuable evidence for Health Technology Assessments (HTAs) supporting reimbursement discussions in additional markets, including NICE (UK) and HAS (France) • Significant expansion of the trained physician base in Germany, supporting long-term adoption and utilisation of OncoSil™ • Increased awareness and engagement among leading pancreatic cancer treatment centres across Europe Strategic Benefits Beyond Revenue Phase III Randomised Controlled Trial ~40 280 24 Months ~$5.6M ~$6.5M 65–70% Study Design Centres Patients Recruitment Trial Revenue Additional Commercial Revenue Gross Margin Opportunity Metric Together, these outcomes have the potential to strengthen OncoSil Medical’s clinical, regulatory and commercial position across Europe while supporting broader patient access to treatment. EXPANDING THE PIPELINE XXI Advancing Towards FDA Approval For dCCA OncoSil Medical reached a significant regulatory milestone during FY26, with the U.S. Food and Drug Administration (FDA) confirming that all outstanding questions relating to the Company’s Humanitarian Device Exemption (HDE) application for distal cholangiocarcinoma (dCCA) have been satisfactorily addressed. The application has now advanced to the final stage of FDA review prior to a potential favourable decision. XXII Understanding the HDE The HDE is a FDA regulatory pathway for medical devices intended to treat or diagnose rare diseases or conditions affecting a small patient population. It enables eligible devices to be approved based on evidence of safety and probable clinical benefit, providing a pathway to make innovative treatments available where large clinical studies may not be feasible. • HDE application submitted for the treatment of dCCA • FDA confirmed all outstanding review questions have been resolved • Application advanced to final FDA review stage • Final device labelling and post-market study updates requested • FDA intends to complete its review within 45 days of final submission • Potential first FDA approval for the OncoSil™ device • Establishes a commercial pathway into the U.S. market • Rare and aggressive cancer with limited treatment options • Eligible for the FDA HDE pathway • Significant unmet clinical need Key Highlights Why dCCA? “The FDA’s confirmation that all outstanding questions have been resolved represents a major achievement for the Company and places OncoSil™ at the final stage of the HDE review process.” Nigel Lange, CEO & Managing Director SCALING FOR GROWTH XXIII Manufacturing Update Building Scale. Improving Margins. During FY26, OncoSil Medical established a new manufacturing capability in Australia using its proprietary manufacturing process and product, representing a key strategic initiative to support future commercial growth and improve production economics. Manufacturing validation runs have now been successfully completed, and the Company is awaiting inspection and regulatory approval. Following approval, the Company expects to commence production of its first commercial doses, representing a significant operational milestone. This new manufacturing capability is expected to be accretive to gross margins while providing greater control over manufacturing processes, quality systems and supply chain management as commercial demand continues to increase. XXIV Q: Why is this manufacturing capability such an important milestone for OncoSil Medical? Q: What are you most looking forward to in the next six months? Renzo DiCarlo: Establishing this manufacturing capability using our proprietary process gives us greater control over our manufacturing processes, quality systems and future scalability. By leveraging our proprietary process and product, we have strengthened our manufacturing capability while maintaining greater oversight of quality, supply and future capacity. This model is expected to reduce our cost of goods sold over time, supporting improved gross margins as commercial volumes increase. As demand for OncoSil™ grows, this capability will become increasingly important in supporting both our operational efficiency and expansion plans. Renzo DiCarlo: Our manufacturing validation runs have now been completed, and we are focused on obtaining the required inspection outcomes and regulatory approval before commencing production of our first commercial doses. Achieving these milestones will mark an important step in OncoSil Medical’s evolution, providing the foundation for improved margins, greater operational control and future growth. 1 Corporate directory Chairman’s letter CEO’s report Directors’ report Auditor’s independence declaration Statement of profit or loss and other comprehensive income Statement of financial position Statement of changes in equity Statement of cash flows Notes to the financial statements Consolidated entity disclosure statement Directors’ declaration Independent auditor’s report to the members of OncoSil Medical Ltd Shareholder information 2 3 6 9 29 30 31 32 33 34 63 64 65 70 CONTENTS 2 Directors Dr Thomas Duthy - Chairman Mr Nigel Lange Ms Lel Smits Joint company secretary Tim Luscombe Nova Taylor Notice of annual general meeting The details of the annual general meeting of OncoSil Medical Ltd are: 1 1:00 (AEDT) Wednesday 18 November 2026 The meeting will be held virtually. Registered office and principal Level 5 place of business 7 Eden Park Drive Macquarie Park, NSW 21 13 Phone: +61 2 8935 9629 Share register Automic Pty Ltd Level 5 126 Phillip Street Sydney NSW 2000 Phone: +61 2 9698 5414 Auditor Crowe Sydney Level 24 1 O’Connell Street Sydney NSW 2000 Solicitors K&L Gates Level 25, South Tower 525 Collins Street Melbourne VIC 3000 Bankers National Australia Bank 330 Collins Street Melbourne VIC 3000 Stock exchange listing OncoSil Medical Ltd shares are listed on the Australian Securities Exchange (ASX code: OSL) Website www.oncosil.com Corporate Governance Statement OncoSil Medical Ltd and the Board of Directors are committed to achieving and demonstrating the highest standards of corporate governance. OncoSil Medical Ltd has reviewed its corporate governance practices against the Corporate Governance Principles and Recommendations (4th Edition) published by the ASX Corporate Governance Council. Details of the corporate governance report is available on the Group website at: https://investors.oncosil.com/corporate-governance CORPORATE DIRECTORY ONCOSIL MEDICAL LTD 30 JUNE 2026 3 DIRECTORS’ REPORT ONCOSIL MEDICAL LTD 30 JUNE 2026 CHAIRMAN’S LETTER Dr Thomas Duthy Non-Executive Chairman OncoSil Medical Dear Shareholders, On behalf of the Board of Directors, I am pleased to present OncoSil Medical Limited’s Annual Report for the financial year ended 30 June 2026. This has been a transformative year for OncoSil Medical. During the year, we achieved several significant regulatory, clinical and commercial milestones that further advanced our mission of improving outcomes for patients suffering from one of the most challenging forms of cancer. These achievements reflect the dedication of our employees, clinicalinvestigators,commercialpartnersandshareholders, all of whom have contributed to the Company’s continued progress. A landmark regulatory year The single most significant event of FY26 was the approval by Australia’s Therapeutic Goods Administration (TGA) of the OncoSil™ device in May 2026. This approval enables inclusion on the Australian Register of Therapeutic Goods for the treatment of unresectable locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. This approval opens our home market for the first time, and with approximately 4,350 new cases of pancreatic cancer diagnosed in Australia each year, the clinical need is both clear and immediate. We anticipate launching in Australia in the first half of the 2027 calendar year. Approval from the Therapeutic Goods Administration (TGA) also validates the quality of our manufacturing operations at our Macquarie Park, New South Wales facility. As we scale production to meet anticipated domestic and export demand, this facility will serve as the backbone of our global supply chain. In Europe, our regulatory position continues to strengthen. The Medical Device Regulation (MDR) certification achieved in January 2025 has already materially simplified commercial treatment initiation across the European Union and United Kingdom, a benefit that flowed directly into our strongest ever sales performance in FY26. We are also progressing regulatory submissions to extend our CE Mark to include use with FOLFIRINOX chemotherapy and percutaneous delivery via Interventional Radiology, both of which are anticipated in the second half of calendar year 2026. In the United States, we were very pleased to announce in June 2026 the US Food and Drug Administration (FDA) confirming that all outstanding questions relating to the Company’s Humanitarian Device Exemption (HDE) application for the treatment of distal cholangiocarcinoma (dCCA) had been satisfactorily addressed. We submitted our HDE package in early July and on 17 August 2026 were very pleased to receive FDA HDE approval for the OncoSil™ device in dCCA. This is a major milestone in the Company’s history with very few ASX listed medical device companies having achieved an FDA approval for a Class III medical device like ours. 4 Clinical momentum converting to commercial outcomes The clinical de-risking of OncoSil™ device has been a multi-year endeavour, and FY26 has seen that investment bear significant fruit. Firstly, the PANCOSIL study, which was an investigator-initiated Phase 1/2 feasibility trial led by Amsterdam UMC. On 18 September 2025 we announced PANCOSIL delivered strong technical feasibility and encouraging preliminary efficacy results. Data was presented at the CIRSE 2025 Congress in Barcelona. As the first study in the world to administer the OncoSil™ device by CT-guided percutaneous injection, PANCOSIL demonstrated that this less invasive delivery approach is both safe and feasible. We are targeting a regulatory submission in the second half of the 2026 calendar year to support percutaneous administration as an approved delivery method, which opens up an entire new clinical speciality group highly familiar with technologies like the OncoSil™ device, namely the interventional radiologists. In June, we announced the results of the TRIPP-FFX study. The study met both of its co-primary endpoints. While the study was designed as a non-comparative trial and was not powered for direct statistical comparison between treatment arms, these outcomes represent an important addition to the growing body of clinical evidence supporting the OncoSil™ device in a disease of profound unmet need. Together with the completion of the investigator-initiated PANCOSIL study, this milestone allows the Board to turn its focus firmly toward regulatory engagement and commercial execution, and the Company is preparing a regulatory submission intended to extend the device’s CE Mark to include use in combination with FOLFIRINOX. Separately, a comparative study presented at Digestive Disease Week 2025 by investigators from the Royal Adelaide Hospital demonstrated superior outcomes for patients treated with OncoSil™ over stereotactic body radiation therapy, with median overall survival of 22 months versus 14 months. This data, which is generated independently by leading clinicians is invaluable in building physician confidence and institutional adoption. On behalf of the Board, I extend my sincere thanks to the patients, clinicians and investigators whose participation made this progress possible. Germany: The pivotal market Germany remains our most strategically significant near- term commercial opportunity. The G-BA (Gemeinsamer Bundesausschuss) sponsored study, commencing in the second half of calendar year 2026, has the potential to unlock access to Germany’s entire public hospital reimbursement system consisting of a market with approximately 20,000 new pancreatic cancer cases per year and one of Europe’s most structured and well- funded healthcare environments. The addressable market opportunity in Germany is conservatively in the order 2.000 to 3.000 patients annually. Commercial momentum in Germany has continued to build. The number of hospitals eligible to seek NUB (Neue Untersuchungs- und Behandlungsmethoden) reimbursement for the OncoSil™ device has grown substantially, and the first successful treatment at Vivantes Neukölln Hospital in Berlin represents one of the largest hospitals in Germany’s largest municipal hospital network. This is an important first step in embedding the OncoSil™ device within leading German oncology centres. We regard the G-BA trial as a potential inflection point not only for Germany but for reimbursement negotiations across other European member states that frequently reference G-BA decisions. Capital management and financial discipline In February 2026, we completed an $8 million capital raise comprising a $6 million placement and a $2.0 million fully underwritten non-renounceable entitlement offer, supported by new and existing substantial shareholders including Pengana Capital Group and Regal Funds Management as cornerstone investors. Your Directors also participated in this raise with a commitment of $0.1 1 million. A further $1.84 million R&D tax incentive refund was received in the second half of the year. CEO Nigel Lange’s decision to convert a 10% salary reduction into ordinary shares reflects a commitment shared across our leadership team: to align management incentives directly with shareholder value creation at this critical stage of the Company’s commercialisation journey. We continue to manage the cost base with discipline. Annualised cost savings of $3.4 million to $3.9 million have been identified for realisation from FY27, ensuring that as revenues grow, the operating leverage in our business model translates into meaningful shareholder returns. Board and governance During FY26 the Board was refreshed to align its composition with the Company’s next phase of clinical and commercial execution. I joined the Board as a Non-Executive Director on 1 1 July 2025 and was subsequently appointed Non-Executive Chairman following Mr Douglas Cubbin’s retirement. As a demonstration of my confidence in OncoSil Medical and my alignment with the interests of shareholders, I elected to sacrifice 100% of my Non-Executive Director fees in favour of equity, taken as OncoSil Medical shares at $1.50 per shar